{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:09:27Z","timestamp":1778940567819,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA263415"],"award-info":[{"award-number":["R21CA263415"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA06927"],"award-info":[{"award-number":["CA06927"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["S10ODO23666"],"award-info":[{"award-number":["S10ODO23666"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100142","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T16:13:15Z","timestamp":1753459995000},"page":"100142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence"],"prefix":"10.1016","volume":"2","author":[{"given":"Pin","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie A","family":"Franzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-1784","authenticated-orcid":false,"given":"Aldana","family":"Vistarop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Efimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SK Abrar","family":"Shahriyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2296-1577","authenticated-orcid":false,"given":"Shengchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazia","family":"Nakhoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1452-9576","authenticated-orcid":false,"given":"Edna","family":"Cukierman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-5486","authenticated-orcid":false,"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3652-5311","authenticated-orcid":false,"given":"Janusz","family":"Franco-Barraza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6651-8617","authenticated-orcid":false,"given":"Juehua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1212","authenticated-orcid":false,"given":"Y. Lynn","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2025.100142_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton's tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100142_bib2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100142_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100142_bib4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hon.2983","article-title":"Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: an expert panel opinion statement","volume":"40","author":"Zinzani","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bneo.2025.100142_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fonc.2019.00689","article-title":"Minimal residual disease in chronic lymphocytic leukemia: a new goal?","volume":"9","author":"Del Giudice","year":"2019","journal-title":"Front Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2025.100142_bib6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2025.100142_bib7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamaoncol.2017.5604","article-title":"Prognostic factors for complete response to ibrutinib in patients with chronic lymphocytic leukemia: a pooled analysis of 2 clinical trials","volume":"4","author":"O'Brien","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100142_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100142_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bneo.2025.100142_bib10","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2025.100142_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cells12010081","article-title":"Cell-in-cell structures in early breast cancer are prognostically valuable","volume":"12","author":"Bauer","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bneo.2025.100142_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13071149","article-title":"Cell-in-cell structures in gastrointestinal tumors: biological relevance and clinical applications","volume":"13","author":"Druzhkova","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.bneo.2025.100142_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.931092","article-title":"Cell-in-cell events in oral squamous cell carcinoma","volume":"12","author":"Siquara da Rocha","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100142_bib14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1186\/s12885-022-09983-6","article-title":"Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer","volume":"22","author":"Song","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bneo.2025.100142_bib15","article-title":"Homotypic cell-in-cell structures as an adverse prognostic predictor of hepatocellular carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100142_bib16","first-page":"1091","article-title":"Subtype-based analysis of cell-in-cell structures in non-small cell lung cancer","volume":"13","author":"Wei","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2025.100142_bib17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2021014251","article-title":"Megakaryocytic emperipolesis as a dyshematopoietic feature in acute myeloid leukemia with inv(16)","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100142_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.seminoncol.2016.02.007","article-title":"Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade","volume":"43","author":"Herman","year":"2016","journal-title":"Semin Oncol"},{"issue":"20","key":"10.1016\/j.bneo.2025.100142_bib19","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100142_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-09-1519","article-title":"Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib","volume":"16","author":"Song","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bneo.2025.100142_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","article-title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","volume":"11","author":"Lu","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.bneo.2025.100142_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41388-022-02565-7","article-title":"SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker","volume":"42","author":"Wu","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.bneo.2025.100142_bib23","series-title":"Predicting clinical response of non-Hodgkin lymphoma with an ex vivo tumor microenvironment model","author":"Nakhoda","year":"2024"},{"issue":"11","key":"10.1016\/j.bneo.2025.100142_bib24","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100142_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1172\/JCI11092","article-title":"Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism","volume":"107","author":"Burger","year":"2001","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.bneo.2025.100142_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103062","article-title":"Phagocytosis by stroma confounds coculture studies","volume":"24","author":"Herbst","year":"2021","journal-title":"iScience"},{"issue":"10","key":"10.1016\/j.bneo.2025.100142_bib27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nrm2504","article-title":"The cell biology of cell-in-cell structures","volume":"9","author":"Overholtzer","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100142_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100142_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"10277","key":"10.1016\/j.bneo.2025.100142_bib30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bneo.2025.100142_bib31","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","article-title":"Clinical pharmacology and PK\/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib","volume":"14","author":"Tam","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100142_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11864-022-00974-0","article-title":"New treatment options for newly-diagnosed and relapsed chronic lymphocytic leukemia","volume":"23","author":"Iskierka-Ja\u017cd\u017cewska","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100142_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","article-title":"BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity","volume":"28","author":"Cheng","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bneo.2025.100142_bib34","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/sj.leu.2401602","article-title":"Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1)","volume":"13","author":"M\u00f6hle","year":"1999","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bneo.2025.100142_bib35","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100142_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","article-title":"Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment","volume":"1863","author":"Ten Hacken","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bneo.2025.100142_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105010","article-title":"CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent","volume":"159","author":"Wang","year":"2020","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.bneo.2025.100142_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-018-0056-9","article-title":"CXCR4 can induce PI3K\u03b4 inhibitor resistance in ABC DLBCL","volume":"8","author":"Kim","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bneo.2025.100142_bib39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.80315","article-title":"Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy","volume":"11","author":"Gutwillig","year":"2022","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.bneo.2025.100142_bib40","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100142_bib41","first-page":"97","article-title":"The role of minimal residual disease in chronic lymphocytic leukemia","volume":"20","author":"Al-Sawaf","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100142_bib42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2025.100142_bib43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2015-02-628677","article-title":"Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy","volume":"126","author":"Cho","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bneo.2025.100142_bib44","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1182\/blood.2020007197","article-title":"Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome","volume":"136","author":"Dale","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2025.100142_bib45","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/bloodadvances.2016003921","article-title":"A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies","volume":"1","author":"Liu","year":"2017","journal-title":"Blood Adv"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:02Z","timestamp":1778938622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000779"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100142","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100142"}}